Global Sample n=137 % (n) VKA n=82 % (n) NOAC n=55* % (n)
P
Age 55.0±13.4 53.3±13.3 57.2±13.2 0.27
Female Sex 29.1% (39) 25.6% (21) 32.7% (18) 0.36
AF type at index procedure 0.013
Paroxysmal 57.5% (77) 40.2% (33) 61.8% (34)
Persistent 41.0% (55) 59.8% (49) 38.2% (21)
Longstanding Persistent 1.5% (2) 2.4% (2) 0%
Baseline ECG in Sinus Rhythm – Index Procedure 58.2% (78) 51.2% (42) 65.4% (36) 0.1
Previous Non-AF ablation 9.8% (13) 9.8% (8) 9.0% (5) 0.71
Previous Alcohol Septal Ablation 4.5% (6) 2.4% (2) 7.3% (4) 0.17
Previous Surgical Myectomy 10.4% (14) 15.8% (13) 1.8% (1) 0.008
LV Apical Aneurysm 1.5% (2) 2.4% (2) 0% 0.51
Congestive HF 15.7% (21) 15.8% (13) 14.5% (8) 0.83
Hypertension 25.4% (34) 19.5% (16) 32.7% (18) 0.79
Diabetes 14.2% (19) 14.6% (12) 12.7% (7) 0.54
Stroke or TIA 10.4% (14) 12.2% (10) 7.3% (4) 0.35
Vascular Disease 9.7% (13) 8.5% (7) 10.9% (6) 0.64
Chronic Kidney Disease 3.8% (5) 3.6% (3) 5.4% (3) 0.61
Obstructive Sleep Apnoea 6.7% (9) 11% (6) 5.4% (3) 0.67
NYHA Class 1.8±0.7 1.8±0.7 1.7±0.7 0.91
CHA2DS2VASc 1.5±1.5 1.3±1.4 1.6±1.6 0.21
HAS-BLED 0.8±0.9 0.8±0.9 0.8±0.9 0.39
Single antiplatelet therapy 3.6% (5) 6.1% (5) 0% 0.08
Dual antiplatelet therapy 0 0% 0% -
Apical Hypertrophy 10.9% (14) 7.3% (8) 10.9% (6) 0.79
Moderate to Severe MR 12.2% (14) 7.3% (6) 14.5% (8) 0.17
Restrictive pattern 21.6% (29) 23.2% (19) 18.2% (10) 0.48
Max LVOT gradient (mm Hg) 14±24 9±13 21±32 0.02
Max LV Thickness (mm) 17±4 17±4 18±3 0.009
LA diameter (mm) 47±7 49±7 45±6 0.5
LVEF 58±9 57±10 59±9 0.017